Pacritinib for chronic myelomonocytic leukemia (CMML)
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a drug called pacritinib for people with CMML. It's for those who haven't had JAK inhibitor therapy before and may have had only one cycle of other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have been diagnosed with CMML
- You have never taken a JAK inhibitor drug
- You have had either no prior treatment or only one cycle of azacitidine/decitabine
- Your white blood cell count is high (≥13,000) or your CMML is intermediate-2 or high risk
- You are willing to use birth control if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (pacritinib and talazoparib) for people with certain bone marrow cancers that have not responded well to standard JAK2 inhibitor therapy. The goal is to see if this combination can help shrink the spleen, improve symptoms, or slow disease progression.
This trial tests whether adding the experimental drug IMM01 to standard azacitidine works better than azacitidine alone for people with chronic myelomonocytic leukemia (CMML). The goal is to see if the combination can help control the disease with manageable side effects.
This trial tests a combination of two drugs, momelotinib and a hypomethylating agent, for people with certain slow-growing blood cancers. If you have a diagnosis like chronic myelomonocytic leukemia or chronic neutrophilic leukemia and have an enlarged spleen, this study might be exploring a new treatment option for you.
This trial tests whether pacritinib works better than hydroxyurea for people with advanced proliferative chronic myelomonocytic leukemia (CMML). It may help if your white blood cell count is high and you have an enlarged spleen, severe symptoms, or low platelets.
This trial tests adding pacritinib to standard hypomethylating agents (azacitidine or decitabine) before a stem cell transplant for people with myeloproliferative neoplasms (MPN) that have progressed to a more advanced phase.
This trial tests a combination of three drugs (pacritinib, venetoclax, and azacitidine) in people whose myeloproliferative neoplasm (MPN) has progressed to a faster-growing, more aggressive phase (accelerated or blast phase). The goal is to see if this combination is safe and effective.
Hear when a new Chronic Myelomonocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.